Novo Nordisk A/S: 2013 long-term, share based incentive programme for the
Senior Management Board
BAGSVAERD, DENMARK -- (Marketwire) -- 03/21/13 -- The long-term,
share-based incentive programme for 2013 for the Senior Management
Board has been approved by the Board of Directors.
Long-term, share-based incentive programme for senior management
As from 2004, members of Novo Nordisk's Executive Management and
other members of the Senior Management Board have participated in a
performance-based incentive programme where a proportion of the
calculated shareholder value creation has been allocated to a joint
pool for the participants. For members of Executive Management and
other members of the Senior Management Board, the joint pool has had
a yearly maximum allocation per participant equal to eight months'
fixed base salary plus pension contribution. At yesterday's Annual
General Meeting, it was approved to raise the potential maximum
allocation per participant from Executive Management to a value equal
to 12 month's fixed base salary plus pension contribution.
Once the joint pool for a given year has been approved by the Board
of Directors, the total cash amount is converted into Novo Nordisk B
shares at market price. The market price is calculated as the average
trading price for Novo Nordisk B shares on NASDAQ OMX Copenhagen in
the open trading window following the release of the full-year
financial results for the year preceding the year of the
performance-based incentive programme. The shares in the joint pool
are locked up for a three-year period before they are transferred to
the participants. In the lock-up period, the Board of Directors may
remove shares from the joint pool in the event of lower than planned
value creation in subsequent years.
Company announcement No 22 / 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
+45 4442 3573
Ken Inchausti (US)
+1 609 514 8316
Kasper Roseeuw Poulsen
+45 4442 4303
Frank Daniel Mersebach
+45 4442 0604
Lars Borup Jacobsen
+45 3075 3479
Jannick Lindegaard (US)
+1 609 786 4575
Press spacebar to pause and continue. Press esc to stop.